Sometimes the best news in medicine doesn't come with flashy breakthroughs but with solid, meaningful progress. That's what GSK Plc (GSK) and Ionis Pharmaceuticals Inc. (IONS) delivered on Wednesday when they announced that bepirovirsen, an investigational treatment for chronic hepatitis B, knocked it out of the park in two large Phase 3 trials.
The studies, dubbed B-Well 1 and B-Well 2, enrolled more than 1,800 patients and hit their primary endpoint. What matters here is that bepirovirsen plus standard care produced statistically significant and clinically meaningful functional cure rates compared to standard care by itself. In patients with lower baseline surface antigen levels (HBsAg ≤1000 IU/ml), the effect was even more pronounced. The safety profile looked acceptable and consistent with earlier studies, which is exactly what you want to hear at this stage.
Why This Matters
Chronic hepatitis B affects over 250 million people worldwide and stands as the leading cause of liver cancer. Current treatments typically require indefinite use, so a finite, six-month therapy would be a genuine game-changer for patients. If bepirovirsen gets approved, it could become the first such option and potentially serve as a backbone for future combination therapies.
GSK licensed bepirovirsen from Ionis back in 2019, and the two have been working together on development ever since. The financial arrangement is structured in typical pharma partnership fashion: Ionis got upfront and milestone payments already, and there's another $150 million waiting in regulatory and sales milestones, plus tiered royalties of 10-12% on net sales. Not a bad deal if this drug makes it across the finish line.
Full data from the studies will be presented at an upcoming scientific conference and published in a peer-reviewed journal. More importantly for investors, GSK plans to file for regulatory approval with health authorities worldwide in the first quarter of 2026.
The Analyst Perspective
William Blair weighed in on Wednesday, noting that with five Phase 3 readouts expected for Ionis in 2026, the company is starting strong with bepirovirsen. Analyst Myles Minter pointed out something interesting: bepirovirsen might be flying under the radar. Gilead Science Inc. (GILD) has Vemlidy on track for over $1 billion in fiscal 2025 revenue, growing at 11% year-over-year. That's a pretty clear signal that there's substantial commercial opportunity in the hepatitis B space.
William Blair maintains an Outperform rating on Ionis, though the firm noted that full data is needed to truly understand bepirovirsen's product profile. Fair enough.
Building Momentum
This isn't Ionis's only recent win. Back in November 2025, the company reported results from pivotal Phase 3 studies of olezarsen for severe hypertriglyceridemia, a condition marked by dangerously high triglyceride levels. Those studies also met their primary endpoint, with olezarsen achieving up to 72% placebo-adjusted mean reduction in fasting triglyceride levels at six months. The company seems to be hitting its stride as it heads into what could be a transformative year.
Investors noticed. Ionis Pharmaceuticals shares climbed 4.06% to $84.80, while GSK shares gained 1.20% to $51.16 at the time of publication on Wednesday.
